Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703654 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL7691833 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| Sulfuric Acid SCHEMBL28705504 | 0.95 | CA2 (0.57) | PPARACA2CA1CA12CA7 | |
| SCHEMBL277303 | 0.92 | CA1 (0.67) | PPARACA2CA1CA12CA7 | |
| SCHEMBL8679104 | 0.92 | CA1 (0.67) | PPARACA2CA1CA12CA7 | |
| SCHEMBL7687552 | 0.85 | RELA (0.62) | PPARACA2CA1CA12CA7 | |
| SCHEMBL4556568 | 0.85 | RELA (0.68) | PPARACA2CA1CA12CA7 | |
| SCHEMBL1753871 | 0.85 | RELA (0.58) | PPARACA2CA1CA12CA7 | |
| SCHEMBL7685651 | 0.83 | RELA (0.71) | PPARACA2CA1CA12CA7 | |
| SCHEMBL9609767 | 0.83 | RELA (0.71) | PPARACA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016044641-A2 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| CN-100350968-C | Modification of feeding behavior | IMP COLLEGE INNOVATIONS LTD (GB) | 2007-11-28 | — | — | CN | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1606248-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| CN-1596119-A | Modification of feeding behavior | IMP COLLEGE INNOVATIONS LTD (GB) | 2005-03-16 | — | — | CN | disclosed |
| WO-2004080951-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
| EP-1457485-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | PPARA 543/4885CA2 565/4885CA1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.